Medicine :: Setting sights on the drugs of the future
Researchers at the University of Nottingham have joined forces with one of the world?s leading pharmaceutical companies, AstraZeneca, to single out potential medicines of the future.
Pharmaceutical
Health :: OneWorld Health selects Odyssey Research for phase 4 study in India
The Institute for OneWorld Health, a US-based non-profit pharmaceutical company that develops drugs for people with neglected diseases in the developing world, today announced the selection of Odyssey Research, a Bismarck, North Dakota-based clinical trial management organization (TMO) with offices in New Delhi, India, to support its upcoming Phase 4 pharmacovigilance and access study of Paromomycin Intramuscular (IM) Injection for the treatment of visceral leishmaniasis (VL) in India.
Cholesterol :: Vitamin B niacin boosts HDL cholesterol good cholesterol
New discoveries offer promise for developing drugs that improve on the therapeutic profile of niacin, the inexpensive, time-tested B-vitamin that boosts levels of HDL cholesterol ? the ?good? cholesterol with the potential to protect people against heart attacks and stroke, scientists reported today.
Angina :: New safety and efficacy data for unique anti-anginal therapy
Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.
Multiple Sclerosis :: Customizable solutions to people with multiple sclerosis
Berlex, Microsoft, and the National Multiple Sclerosis Society Embark on Landmark Collaboration to Help People with MS Maintain Their Health and Stay Connected.
Multiple Sclerosis :: Interferon beta-1b for patients with multiple sclerosis
Novartis to launch its own branded version of a leading multiple sclerosis therapy through agreement with Bayer Schering Pharma.
Prostate Cancer :: Compound found in high-fiber foods shows promise against prostate cancer
A dietary component found in most whole grain foods, beans, nuts and other high-fiber items shows promise in animal studies as a potent weapon for preventing prostate cancer.
Weight Loss :: Sanofi’s Acomplia reimbursable in France for obese and type 2 diabetic patients
Sanofi-aventis announced that Acomplia? 20mg (rimonabant), the first drug in a new therapeutic class, the selective cannabinoid-1 receptor antagonists, has now been included in the list of pharmaceutical products reimbursable by the Social Security, by virtue of a decree dated March 22, 2007, published in the Official Journal of the French Republic.
Pharmaceutical :: Disclosure of pharmaceutical company payments to physicians ?
Laws in two states requiring disclosure of pharmaceutical company payments to physicians do not provide the public with easy access to payment information and are of limited quality when accessed, according to a study in the March 21 issue of JAMA.
Osteoporosis :: IOF World Congress on Osteoporosis to be held for first time in Asia
For the first time, the IOF World Congress on Osteoporosis will be held in Asia. The congress will be held in Bangkok, Thailand, Dec. 3-7, 2008.The second announcement for the IOF WCO was released today, and is available online.